Connect with us

Technology

Generate:Biomedicines Provides Update on its Platform and Pipeline Powered by AI at the 43rd Annual J.P. Morgan Healthcare Conference

Published

9 hours ago

on

SOMERVILLE, Mass., Jan. 9, 2025 /PRNewswire/ — Generate:Biomedicines (“Generate”) today announced that Mike Nally, Chief Executive Officer, will provide an update on the company’s platform, which combines generative AI and experimental innovation, and its advancing pipeline at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13 at 7:30am PST. The Generate Platform has proven its ability to produce unique and differentiated molecules, allowing the company to advance multiple programs into clinical development and establishing programmable biology as a catalyst for new possibilities in medicine.

“We are at the forefront of a biological revolution,” said Mike Nally, CEO of Generate:Biomedicines.

“We are at the forefront of a biological revolution,” said Mike Nally, CEO of Generate:Biomedicines. “Generative AI is enabling us to tackle some of the toughest challenges in drug discovery, from historically undruggable and hard-to-drug targets to optimizing molecules with unprecedented precision. As more of our programs advance into the clinic, we’re demonstrating how our platform is creating differentiated medicines — while at the same time transforming the very process by which they are made.”

The Generate Platform seamlessly integrates machine learning, high-throughput experimentation, and at-scale structural determination to enable programmable biology. With nearly 20 programs underway and multi-target collaborations with Amgen and Novartis, the Company will share its progress addressing high-value therapeutic areas with significant unmet patient need, including:

Immunology & Inflammation (I&I) Portfolio: Generate is advancing multiple differentiated molecules for respiratory, dermatology, and gastrointestinal indications. These programs focus on six-monthly dosing and best-in-class monotherapies to drive market expansion, improve adherence, and support long-acting combination approaches for better efficacy and outcomes, including:
GB-0895 (anti-TSLP): Completing Phase 1 in mild-to-moderate asthma patients, demonstrating potential as a foundational therapy for future combinations.GB-7624 (anti-IL-13): Preparing for a Phase 1 trial in early 2025, targeting atopic dermatitis.Preclinical mono and combo portfolio: Advancing programs for TL1A, OX40L and combinations of TSLP and IL-13 and TL1A and IL-23 for various indications.Infectious Diseases: GB-0669, the first AI-generated viral neutralizing antibody targeting SARS-CoV‑2, achieved positive Phase 1 results, providing compelling data supporting The Generate Platform. The antibody overcame traditional biologics limitations, successfully reaching a previously undruggable target with speed and precision while remaining effective across variants and related coronaviruses. Results were presented at IDWeek 2024.

Generate is deploying its platform towards advancement of innovative programs across multiple therapeutic areas including:

Its MMAE ADC payload neutralizer aims to improve therapeutic index by reducing payload-mediated toxicity without impacting ADC efficacy, potentially allowing for more sustained dosing of existing medicines and/or higher dosing of novel agents.Generate has also designed best-in-class CAR-T cell therapies with enhanced stability, expression, and function, each in ~4–6 months, a fraction of the time typically required.

Continuing to expand platform capabilities, Generate has achieved unprecedented scale across experimental and machine learning domains, pushing the boundaries of CryoEM, multiplexed biological assays, and protein manufacturing beyond industry or academia state of the art. Recent advances in in-house foundational and data-driven models have further enhanced the company’s technology stack across optimization and de novo generation. By building on these advancements, Generate is further enhancing its ability to address complex biological challenges and accelerate the impact of programmable biology across therapeutic areas.

About Generate:Biomedicines
Generate:Biomedicines is a technology company founded at the intersection of machine learning, biological engineering and medicine that is advancing a new era of programmable biology to engineer better medicines for patients, faster. The Generate Platform’s infusion of technology into biology allows us to address historically undruggable and hard-to-drug targets as well as known targets in new and more effective ways. The platform has enabled the generation of a broad pipeline of therapies across multiple therapeutic areas and protein-based modalities, addressing health challenges out of reach of traditional approaches. Founded by Flagship Pioneering in 2018, Generate is a clinical-stage company leading a fundamental shift from drug discovery to drug generation. Learn more at  www.generatebiomedicines.com or follow us on X, LinkedIn and YouTube.

Generate:Biomedicines: Megan McLaughlin, Media Relations
Email: pr@generatebiomedicines.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/generatebiomedicines-provides-update-on-its-platform-and-pipeline-powered-by-ai-at-the-43rd-annual-jp-morgan-healthcare-conference-302346582.html

SOURCE Generate:Biomedicines

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

TriNetX’s Founding CEO Announces Plans to Step Down

Published

14 minutes ago

on

January 9, 2025

By

After 11 Years, Gadi Lachman to Conclude Operating Role, Remain on TriNetX’s Board

CAMBRIDGE, Mass., Jan. 9, 2025 /PRNewswire/ — TriNetX, the largest global source of real-world data, today announced that Gadi Lachman, the Company’s Founder, President and CEO, will step down from his operating role on March 31, 2025. Gadi founded TriNetX in 2014 and has served as President and CEO in the succeeding 11 years. Gadi will continue to serve on TriNetX’s Board of Directors and will be an Advisor to Carlyle, TriNetX’s majority investor.

“It has been an honor to build TriNetX and be part of such an outstanding team. I want to thank TriNetX’s employees, customers, and shareholders for the support they have shown me. With the talent and passion of our people I am immensely confident in TriNetX’s continued success,” said Lachman. “Together, we have built the largest global platform for clinical research, with data from over 25 countries and tens of millions of queries a month. Our solutions are moving clinical research to a whole different level and saving lives on a massive scale, across all therapeutic areas.”

During the transition period, Jeff Margolis, a current TriNetX Director, will serve as Executive Chairman to ensure continuity in leadership and governance while a CEO search is conducted.

Margolis said, “I have had the distinct privilege of serving on the Board alongside Gadi and partnering with him for 11 years. On behalf of the Board, we thank Gadi for shaping and leading TriNetX to become the world’s top ecosystem of real-world data and real-world evidence serving life sciences and the broader healthcare industry. I look forward to working with him and the rest of the Board over the next months to execute a successful transition of leadership.”

Joe Bress, Partner and Global Co-Head of Healthcare for Carlyle, TriNetX’s lead investor, added, “We have been thrilled to partner with Gadi since our initial investment in TriNetX over four years ago. Thanks to his disciplined leadership, TriNetX is one of the few companies that has sustained profitability even during periods of high growth. Gadi has built the company up to an exciting point, paving the way for a new leader to take the business into its next chapter of growth and success.”

Through this leadership transition, TriNetX remains steadfast in its mission to advance global healthcare through the power of real-world data. The Board, leadership team, and employees are united in their commitment to driving continued innovation and delivering success for customers and partners, all while building on Gadi’s exceptional legacy.

About TriNetX, LLC

TriNetX is a global network of healthcare organizations and life sciences companies dedicated to advancing real-world research and expediting the development of new therapies. Through its self-service, HIPAA-, GDPR-, and LGPD-compliant platform of federated deidentified and anonymous electronic health record datasets and consulting partnerships, TriNetX empowers its global community to improve clinical trial protocol design, streamline trial operations, refine safety signals, and enrich real-world evidence generation. For more information, please visit TriNetX at www.trinetx.com or follow TriNetX on LinkedIn.

Media Contact
TriNetX
Michelle Fleming, Chief Marketing Officer
Email: Michelle.Fleming@TriNetX.com

Logo – https://mma.prnewswire.com/media/542641/TriNetX_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/trinetxs-founding-ceo-announces-plans-to-step-down-302347367.html

Continue Reading

Technology

Stellus Private Credit BDC Announces $0.36 First Quarter 2025 Regular Dividend, Payable Monthly in Increments of $0.12 in January, February, and March 2025

Published

14 minutes ago

on

January 9, 2025

By

HOUSTON, Jan. 9, 2025 /PRNewswire/ — Stellus Private Credit BDC (“the Company”) announced that its Board of Trustees has declared a monthly dividend of $0.12 for each of January, February, and March, totaling $0.36 per share in the aggregate for the first quarter of 2025. The regular dividend of $0.36 per share will be paid to shareholders of record in January, February, and March 2025.

Summary of First Quarter 2025 Regular Monthly Dividends

Declared

Record Date

Payment Date

Amount per Share

1/9/2025

1/10/2025

1/31/2025

$0.12

1/9/2025

2/3/2025

2/28/2025

$0.12

1/9/2025

3/3/2025

3/31/2025

$0.12

About Stellus Private Credit BDC

The Company is an externally-managed, closed-end, non-diversified investment management company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended. The Company’s investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation by investing primarily in private middle-market companies (typically those with $5.0 million to $50.0 million of EBITDA (earnings before interest, taxes, depreciation and amortization)) through first lien (including unitranche) loans, second lien loans and unsecured debt financing, with corresponding equity co-investments. The Company’s investment activities are managed by its investment adviser, Stellus Private BDC Advisor, LLC.

Forward-Looking Statements

Statements included herein may contain “forward-looking statements” which relate to future performance or financial condition. Statements other than statements of historical facts included in this press release, including statements about COVID-19 and its impacts, may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of assumptions, risks and uncertainties, which change over time. Actual results may differ materially from those anticipated in any forward-looking statements as a result of a number of factors, including those described from time to time in filings by the Company with the Securities and Exchange Commission including the final prospectus that will be filed with the Securities and Exchange Commission. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Contacts
Stellus Private Credit BDC
W. Todd Huskinson, Chief Financial Officer
(713) 292-5414
thuskinson@stelluscapital.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/stellus-private-credit-bdc-announces-0-36-first-quarter-2025-regular-dividend-payable-monthly-in-increments-of-0-12-in-january-february-and-march-2025–302347311.html

SOURCE Stellus Private Credit BDC

Continue Reading

Technology

MongoDB, Inc. to Present at the 27th Annual Needham Growth Conference

Published

14 minutes ago

on

January 9, 2025

By

NEW YORK, Jan. 9, 2025 /PRNewswire/ — MongoDB, Inc. (NASDAQ: MDB) today announced that Chief Operating Officer and Chief Financial Officer, Michael Gordon, and Senior Vice President of Finance, Serge Tanjga, will present virtually at the 27th Annual Needham Growth Conference.

The MongoDB presentation is scheduled for Thursday, January 16, 2025, at 3:45 p.m. Eastern Time. A live webcast of the presentation will be available on the Events page of the MongoDB investor relations website at https://investors.mongodb.com/news-events/events. A replay of the webcast will also be available for a limited time.

About MongoDB
Headquartered in New York, MongoDB’s mission is to empower innovators to create, transform, and disrupt industries by unleashing the power of software and data. Built by developers, for developers, MongoDB’s developer data platform is a database with an integrated set of related services that allow development teams to address the growing requirements for today’s wide variety of modern applications, all in a unified and consistent user experience. MongoDB has tens of thousands of customers in over 100 countries. The MongoDB database platform has been downloaded hundreds of millions of times since 2007, and there have been millions of builders trained through MongoDB University courses. To learn more, visit mongodb.com.

Investor Relations
Brian Denyeau
ICR for MongoDB
646-277-1251
ir@mongodb.com

Media Relations
MongoDB PR
press@mongodb.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/mongodb-inc-to-present-at-the-27th-annual-needham-growth-conference-302347475.html

SOURCE MongoDB, Inc.

Continue Reading

Trending